Company Number: 12612221

Analysis Date: 2025-07-20 15:59 UTC

Financial Health Assessment for Astar Pharma Limited

---

1. Financial Health Score: B

Explanation:
Astar Pharma Limited demonstrates a generally healthy financial position with positive net current assets and growing shareholders' funds over recent years. The company maintains a comfortable liquidity position with cash exceeding current liabilities by a significant margin. However, the relatively small scale of operations (no employees, minimal share capital) and absence of detailed profitability data suggest caution, limiting the rating to a solid "B" rather than an "A."

---

2. Key Vital Signs

Metric	2024 Value (£)	Interpretation
Cash at Bank	13,061	Healthy cash reserves, indicating good liquidity ("healthy pulse") to meet short-term obligations.
Current Liabilities	4,021	Low short-term debt burden relative to cash assets, showing no signs of financial distress.
Net Current Assets	9,040	Positive working capital ("strong heartbeat"), implying the company can cover short-term liabilities comfortably.
Shareholders' Funds	9,040	Growing equity base, signaling accumulation of retained earnings and financial strength.
Share Capital	2	Minimal capital injection, typical for a small private company; growth relies on earnings and reserves.
Employees	0	No staff employed, suggesting either an early-stage or contracting business model, which affects operational risk.

---

3. Diagnosis

• Liquidity & Solvency:
  The company shows no symptoms of liquidity stress, with cash nearly three times current liabilities. This "healthy cash flow" implies good short-term financial stability. The positive net current assets and shareholders’ funds indicate solvency and no immediate risk of insolvency.

• Growth & Capital Structure:
  The rise in shareholders’ funds from £2 (2020) to £9,040 (2024) reflects steady retention of earnings or capital accumulation over four years, demonstrating a strengthening financial "immune system." However, the tiny share capital and no employees suggest the company is in a developmental or research phase rather than full commercial operation.

• Profitability & Operations:
  The absence of detailed profit and loss data (not filed as per small company exemptions) limits insight into operational performance. The company’s small financial scale and no staff might mean limited revenue-generating activities or reliance on external contractors and investment.

• Governance & Control:
  Directors double as key controllers, both scientists, which is typical for specialist professional entities. The control structure is balanced and transparent with no red flags in governance.

---

4. Recommendations

• Enhance Financial Transparency:
  Consider voluntarily publishing more detailed financial statements including profit and loss to provide stakeholders with clearer insight into operational performance and future prospects.

• Diversify Funding Sources:
  Given minimal share capital, exploring additional equity or debt funding could strengthen the capital base and support growth or operational scaling.

• Operational Expansion:
  If business model allows, hiring key staff or contractors could help drive growth, but must be managed carefully to avoid cash flow strain.

• Cash Flow Management:
  Maintain the current discipline in managing receivables and payables to preserve liquidity, especially as the company grows.

• Strategic Planning:
  Develop a longer-term business plan incorporating revenue projections, investment needs, and risk management to improve financial resilience.

---

Summary Medical Analogy

Astar Pharma Limited’s financial "vital signs" indicate a firm and healthy "heartbeat" with strong liquidity and equity growth. The company currently enjoys a stable "circulatory system" of cash and assets versus liabilities, showing no symptoms of financial distress. However, the firm remains in a "developmental stage," akin to a young patient with good baseline health but requiring monitoring and strategic care to ensure continued growth and operational vitality.

---